$2.02
2.02%
Nasdaq, Jan 02, 10:19 pm CET
ISIN
US45256X1037
Symbol
IBRX

ImmunityBio Inc Stock price

$2.02
-0.07 3.35% 1M
-0.62 23.48% 6M
+0.04 2.02% YTD
-0.55 21.40% 1Y
-3.05 60.16% 3Y
-11.71 85.29% 5Y
-13.73 87.17% 10Y
-32.62 94.17% 20Y
Nasdaq, Closing price Fri, Jan 02 2026
+0.04 2.02%
ISIN
US45256X1037
Symbol
IBRX
Industry

New AI Insights on ImmunityBio Inc Insights AI Insights on ImmunityBio Inc

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Key metrics

Basic
Market capitalization
$2.0b
Enterprise Value
$2.6b
Net debt
$561.8m
Cash
$257.8m
Shares outstanding
985.0m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
24.1 | 17.6
EV/Sales
30.9 | 22.6
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
-127.7%
Return on Equity
84.6%
ROCE
-56.5%
ROIC
-102.3%
Debt/Equity
-1.6
Financials (TTM | estimate)
Revenue
$82.6m | $113.1m
EBITDA
$-258.7m | -
EBIT
$-260.7m | $-270.4m
Net Income
$-348.6m | $-454.1m
Free Cash Flow
$-324.8m
Growth (TTM | estimate)
Revenue
1,026.3% | 666.9%
EBITDA
27.8% | -
EBIT
27.6% | 21.4%
Net Income
40.7% | -9.8%
Free Cash Flow
25.2%
Margin (TTM | estimate)
Gross
99.6%
EBITDA
-313.4% | -
EBIT
-315.8%
Net
-422.3% | -401.4%
Free Cash Flow
-393.4%
More
EPS
$-0.4
FCF per Share
$-0.3
Short interest
33.0%
Employees
680
Rev per Employee
$20.0k
Show more

Is ImmunityBio Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,082 stocks worldwide.

ImmunityBio Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a ImmunityBio Inc forecast:

10x Buy
91%
1x Hold
9%

Analyst Opinions

11 Analysts have issued a ImmunityBio Inc forecast:

Buy
91%
Hold
9%

Financial data from ImmunityBio Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
83 83
1,026% 1,026%
100%
- Direct Costs 0.37 0.37
-
0%
82 82
-
100%
- Selling and Administrative Expenses 153 153
4% 4%
185%
- Research and Development Expense 188 188
8% 8%
228%
-259 -259
28% 28%
-313%
- Depreciation and Amortization 2 2
0% 0%
2%
EBIT (Operating Income) EBIT -261 -261
28% 28%
-316%
Net Profit -349 -349
41% 41%
-422%

In millions USD.

Don't miss a Thing! We will send you all news about ImmunityBio Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

ImmunityBio Inc Stock News

Neutral
Business Wire
7 days ago
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that OncoDaily has recognized Dr. Patrick Soon-Shiong as being one of “The 100 Most Influential People in Oncology in 2025.” Soon-Shiong is the company's Founder, Executive Chairman and Global Chief Scientific and Medical Officer, and is a global thought leader in ad...
Neutral
Business Wire
20 days ago
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced treatment with ANKTIVA® (nogapendekin alfa inbakicept-pmln) plus Bacillus Calmette-Guérin (BCG) demonstrates efficacy at 12 and 36 months, including disease-free survival (DFS), disease-specific survival (DSS), long-term progression-free survival (PFS), and high cystectomy av...
Neutral
Business Wire
24 days ago
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio (NASDAQ: IBRX), a leading immunotherapy company, announced today that the European Medicines Agency has recommended granting a conditional marketing authorization in the EU for ANKTIVA® (nogapendekin alfa inbakicept) in combination with Bacillus Calmette-Guérin (BCG) for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC...
More ImmunityBio Inc News

Company Profile

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in Culver City, CA.

Head office United States
CEO Richard Adcock
Employees 680
Founded 2014
Website immunitybio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today